Eisai Resubmits Aricept sNDA For Severe Alzheimer’s
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai has submitted a reformatted electronic supplemental new drug application for Aricept (donepezil), the firm announced Dec. 19
You may also be interested in...
FDA’s Refusal-To-File Slows Acorda’s Promising Niche MS Drug
Firm may need to refile NDA for mobility-boosting Fampridine-SR.
FDA’s Refusal-To-File Slows Acorda’s Promising Niche MS Drug
Firm may need to refile NDA for mobility-boosting Fampridine-SR.
Pfizer Acquires TransTech RAGE Compounds
TransTech Pharma’s receptor for advanced glycation end products antagonists have potential to treat Alzheimer’s disease.